The table below shows Xenon Pharmaceuticals Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$88.90M
-$61.65M
-$46.19M
-$34.41M
-$18.43M
-$20.71M
Capital expenditure
$133.00K
$43.00K
$188.00K
$2.21M
$212.00K
$404.00K
Investing cash flow
-$407.28M
$34.51M
-$43.19M
$46.62M
-$48.89M
-$55.10M
Dividends paid
-
-
-
XENE operating cash flow (10-K history)
Xenon Pharmaceuticals Inc. reported operating cash flow of -$279.12M for fiscal year 2025. That is down 53.9% from -$181.39M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$28.73M (FY 2017) to -$279.12M. Figures come from the company's audited annual reports as filed with the SEC.